Paclitaxel: a review of adverse toxicities and novel delivery strategies.
about
Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancerNovel delivery strategies for glioblastomaPharmacogenomics of chemotherapeutic susceptibility and toxicityCys34-PEGylated Human Serum Albumin for Drug Binding and DeliveryUltrasound-mediated destruction of LHRHa-targeted and paclitaxel-loaded lipid microbubbles for the treatment of intraperitoneal ovarian cancer xenograftsF10, a novel hydatidiform mole-associated gene, inhibits the paclitaxel sensitivity of A549 lung cancer cells by downregulating BAX and caspase-3.Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancerComparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinomaStrategy for increasing drug solubility and efficacy through covalent attachment to polyvalent DNA-nanoparticle conjugates.Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles.Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models.Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, Nanoxel(TM).Inhibition study on insulin fibrillation and cytotoxicity by paclitaxel.Development of a mouse model for assessing fatigue during chemotherapy.KUD773, a phenylthiazole derivative, displays anticancer activity in human hormone-refractory prostate cancers through inhibition of tubulin polymerization and anti-Aurora A activity.Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer.Cancer cell surface induced peptide folding allows intracellular translocation of drug.Comparative vascular responses three months after paclitaxel and everolimus-eluting stent implantation in streptozotocin-induced diabetic porcine coronary arteries.Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells.A critical review of lipid-based nanoparticles for taxane delivery.Paclitaxel-conjugated PAMAM dendrimers adversely affect microtubule structure through two independent modes of action.Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.From fighting depression to conquering tumors: a novel tricyclic thiazepine compound as a tubulin polymerization inhibitorCdk2 acts upstream of mitochondrial permeability transition during paclitaxel-induced apoptosisA 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs.The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells.Fatigue and sleep during cancer and chemotherapy: translational rodent modelsBreast cancer cells evade paclitaxel-induced cell death by developing resistance to dasatinib.Recent advances of cocktail chemotherapy by combination drug delivery systems.Development and evaluation of a novel biodegradable sustained release microsphere formulation of paclitaxel intended to treat breast cancer.Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial.Synergistic locoregional chemoradiotherapy using a composite liposome-in-gel system as an injectable drug depot.TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.Extracellular biosynthesis of gadolinium oxide (Gd2O3) nanoparticles, their biodistribution and bioconjugation with the chemically modified anticancer drug taxol.Macromolecules as taxane delivery systems.Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication.Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis.Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy.High-throughput cell mechanical phenotyping for label-free titration assays of cytoskeletal modifications
P2860
Q24621947-215FAC04-EA63-4B78-8513-C0C9A09F78E9Q27006099-7CDFEB98-E359-4713-A1B5-BA59B68D0A18Q27025558-707D4B59-2E59-41DC-A88C-9770CADD6CF6Q27301475-E28B91C9-1A9D-4D30-A24D-75D89C59ED63Q30421398-812055A3-50FC-4E54-A081-E86CC7D6A4E9Q32178099-4C58F2A2-5052-4AE9-A41C-B460D9EBF455Q33621256-9392B385-334E-4A3B-9B8A-3EDD876399D3Q33913820-6EC7AC16-C82C-426C-9111-ECBD80596CE7Q33980411-30253A04-35FB-42BE-B11B-AE8BBB412667Q34170184-E458D971-1B68-4580-B75F-181AFB51CC30Q34265716-5C2CE17C-0414-439B-9140-B5728F2B4154Q34291868-30A15499-6295-4D90-8A8D-8DA488315C77Q34404870-D2A11231-1223-4C32-8502-AFCD5722ABD9Q34819916-C242D2C4-BC01-46C2-B107-8192061B34D9Q35005238-5521A538-24C6-4403-8E7F-BCAD2CAD96CFQ35565766-3636B033-6C85-4213-BE0E-52E484502DA3Q35691164-DE626F53-2AAA-46BB-9E31-D62D65641538Q36146253-1BE7487C-FBCC-485D-A310-0B2FAA6F44B4Q36222691-C1441AD0-CF51-4F9C-B9CA-5278B52DBC8DQ36360764-46619B91-F7E0-4B17-B215-F9048EEE7FBEQ36702085-048C4037-8781-4F26-AE02-8C39E3E013D6Q36705677-F178D865-01F2-4BB2-8CBB-0F428659BA53Q36775000-B6684761-CE5C-499F-AA62-9B8497CCA813Q36922743-31D5EBFB-13EE-459A-9626-EE29DA4B72B3Q36976738-806A4EC8-88F7-45D9-A169-2DF363E0C021Q37190466-042B26D7-C780-4264-A628-B31EDA9DE600Q37203219-67A9E975-EE67-4FAC-8C44-DA5B70F1D94FQ37205970-EC459D65-7104-48A8-B6BB-D173AA4AEF4EQ37206908-B509DD60-BB17-4115-AD2B-08D74B6ADF2CQ37254496-6CFF573F-3282-489F-B925-046E79F33994Q37401487-3AFB03A4-F300-4B41-B0A0-C674405CC932Q37474708-32EDB4E5-FBD0-402A-A26F-F40297F5988BQ37480340-2C12A3BF-AC48-41C6-9623-87B308376AFDQ37723574-404E3F69-53DE-4176-BED9-070B4EB0DE60Q37818236-EC26CF10-5891-4EA4-AB21-4CD28C8C9BCDQ37841631-B58FC6AA-3175-47B9-8536-2185F772E57AQ37877271-2CBB671F-02AC-4887-B9E4-980B58048CCCQ38314414-C542C232-0C82-49AF-A151-D5CBFEA99339Q38407471-D5A96F20-C882-42F2-A5AB-A833777B200CQ38705973-E3364295-723A-4A7B-ABB0-0B710F4BB0D6
P2860
Paclitaxel: a review of adverse toxicities and novel delivery strategies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Paclitaxel: a review of adverse toxicities and novel delivery strategies.
@en
type
label
Paclitaxel: a review of adverse toxicities and novel delivery strategies.
@en
prefLabel
Paclitaxel: a review of adverse toxicities and novel delivery strategies.
@en
P2093
P2860
P356
P1476
Paclitaxel: a review of adverse toxicities and novel delivery strategies
@en
P2093
Betty M Tyler
Henry Brem
James E Han
Violette M Renard
P2860
P304
P356
10.1517/14740338.6.5.609
P407
P577
2007-09-01T00:00:00Z